Kim Eunjoo, Cheon Keun-Ah, Joung Yoo Sook, Kim Joo-Young, Song Dong-Ho
*Department of Psychiatry and Institute of Behavioral Science in Medicine, Yonsei University College of Medicine; and †Department of Psychiatry, Sungkyunkwan University School of Medicine, Seoul; and ‡Yonsei Junior Clinic, Seongnam, Korea.
Clin Neuropharmacol. 2015 Jan-Feb;38(1):30-5. doi: 10.1097/WNF.0000000000000064.
This study examined the effect of osmotic-controlled release oral delivery system-methylphenidate (OROS-MPH) on the adaptive functioning of children and adolescents with attention-deficit/hyperactivity disorder (ADHD) and investigated the relationship between reduced ADHD symptoms and improvements in functioning and factors that are predictive of functional improvement.
This study was a prospective, multicenter, open-label study of 116 children with ADHD treated with OROS-MPH for 12 weeks. Attention-deficit/hyperactivity disorder symptoms, functional impairment, and other comorbid disorders were evaluated using various clinical scales. Correlational and multiple regression analyses were conducted to examine the relationship between symptomatic versus functional changes after OROS-MPH treatment.
Correlation analysis showed a moderately strong association between changes in the ADHD core symptoms versus functional measure scores (r = -0.65). The self-control subscale of the Life Participation Scale showed higher correlations with symptomatic measures than did the happy/social subscale. Functional outcomes were impacted by several factors including the baseline severity of ADHD symptoms, changes in ADHD, and oppositional defiant symptoms after treatment. Attention was more associated with functional outcomes than hyperactivity/impulsivity.
Treatment with OROS-MPH was associated with symptomatic functional changes that were moderately correlated; therefore, symptomatic functional outcomes appear to be partially overlapped but distinct domains. Consequently, functional measures should be incorporated as important outcome measures in future treatment studies; the importance of treatments targeting functional improvement should be emphasized in the treatment of children with ADHD.
本研究探讨渗透泵控释口服给药系统-哌甲酯(OROS-MPH)对注意力缺陷多动障碍(ADHD)儿童和青少年适应性功能的影响,并研究ADHD症状减轻与功能改善之间的关系以及预测功能改善的因素。
本研究是一项前瞻性、多中心、开放标签研究,对116例接受OROS-MPH治疗12周的ADHD儿童进行研究。使用各种临床量表评估注意力缺陷多动障碍症状、功能损害和其他共病。进行相关性和多元回归分析以检验OROS-MPH治疗后症状与功能变化之间的关系。
相关性分析显示ADHD核心症状变化与功能测量得分之间存在中等强度的关联(r = -0.65)。生活参与量表的自我控制子量表与症状测量的相关性高于快乐/社交子量表。功能结果受多种因素影响,包括ADHD症状的基线严重程度、ADHD的变化以及治疗后对立违抗症状。注意力比多动/冲动与功能结果的相关性更强。
OROS-MPH治疗与症状性功能变化相关,且相关性中等;因此,症状性功能结果似乎部分重叠但又有所不同。因此,在未来的治疗研究中应将功能测量作为重要的结果测量指标;在ADHD儿童的治疗中应强调针对功能改善的治疗的重要性。